| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
ATOX1-IN-1 (compound 8) (48 hours) inhibited the activity of HepG2 and Huh7 liver cancer cells, with IC50 values of 16.5 μM and 22.0 μM, respectively, and showed higher selectivity for cancer cells than immortalized hepatocytes THLE-2[1]. ATOX1-IN-1 (10 μM) combined with 10 μM cisplatin showed more significant anti-proliferative and pro-apoptotic effects on HepG2 and Huh7 liver cancer cells[1]. ATOX1-IN-1 (5-15 μM) inhibited the NOTCH1/HES1 signaling pathway in HepG2 and Huh7 liver cancer cells in a concentration-dependent manner in vitro, and reduced the mRNA and protein expression levels of NOTCH1 and HES1[1]. ATOX1-IN-1 (5-15 μM) increased intracellular copper levels in HepG2 and Huh7 liver cancer cells in a concentration-dependent manner[1]. ATOX1-IN-1 (5-15 μM) enhances DNA methylation of the NOTCH1 promoter in HepG2 and Huh7 hepatocellular carcinoma cells in an in vitro concentration-dependent manner [1].
|
|---|---|
| ln Vivo |
ATOX1-IN-1 (10 mg/kg; intraperitoneal injection; once daily for 10 days) showed antitumor activity in the HepG2 liver cancer xenograft model and produced a synergistic and well-tolerated antitumor effect when used in combination with cisplatin [1].
|
| Animal Protocol |
Animal/Disease Models:BALB/c nude mice (6-8 weeks old, 18-22 g, balanced sex ratio, subcutaneous HepG2 xenograft model) [1]
Doses: 10 mg/kg Route of Administration: Intraperitoneal injection; once daily for 10 consecutive days Experimental Results: Compared with the control group, tumor volume and expression of proliferation markers (Ki67, PCNA) were reduced. When combined with cisplatin, the tumor inhibition effect was significantly better than that of monotherapy. The tumor volume in the combined treatment group was the smallest, the expression of Ki67 and PCNA was the lowest, and no obvious pathological changes were observed in the major organs (heart, liver, lung, kidney, gastrointestinal tract). |
| References |
| Molecular Formula |
C33H26N2O6
|
|---|---|
| Molecular Weight |
546.57
|
| CAS # |
956181-19-4
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
O=C(N[C@@H](CC1=CNC2=C1C=CC=C2)C(OC3=CC=C(C(C=CC=C4)=C4C(O5)=O)C5=C3C)=O)OCC6=CC=CC=C6
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8296 mL | 9.1480 mL | 18.2959 mL | |
| 5 mM | 0.3659 mL | 1.8296 mL | 3.6592 mL | |
| 10 mM | 0.1830 mL | 0.9148 mL | 1.8296 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
